Tacit Therapeutics Raises $19M Series A to Advance RNA Gene Therapy Platform for Genetic Diseases
Tacit Therapeutics, a South San Francisco-based biotechnology company developing RNA-targeted gene therapies for serious genetic diseases, has raised approximately $19 million in Series A financing as it advances its Splicing-Directed Repair platform toward clinical development. The funding reflects growing investor interest in next-generation gene therapy approaches that aim to repair genetic mutations at the RNA level rather than relying solely on traditional DNA editing techniques.
The Series A round was led by Eisai Innovation, the corporate venture arm of the global pharmaceutical company Eisai, alongside participation from Civilization Ventures and KdT Ventures. The involvement of both strategic pharmaceutical investors and specialist biotech venture firms underscores confidence in Tacit Therapeutics’ approach to addressing genetic diseases through RNA splicing modulation.
Founded in 2021, Tacit Therapeutics is building its platform around a core biological insight: human cells naturally perform RNA splicing, a process that can be harnessed to repair defective genetic sequences. The company’s proprietary Splicing-Directed Repair technology is designed to redirect this process to correct mutations that cause a wide range of inherited diseases. Unlike conventional gene editing methods, which often involve permanent changes to DNA, Tacit’s RNA-based approach aims to reduce safety risks such as immune reactions and off-target effects.
The company’s lead programs focus on developing treatments for neurological and rare genetic disorders, including conditions where current therapeutic options are limited or ineffective. Tacit believes its platform could enable the development of broadly applicable therapies capable of addressing multiple diseases using a common underlying mechanism. This scalability has been a key factor in attracting early-stage investor support.
The $19 million financing is expected to support continued platform development, expansion of the company’s scientific team, and advancement of preclinical research programs. In addition, the capital will be used to further validate Tacit’s RNA trans-splicing approach and prepare for eventual clinical trials. The company has also been working to expand its intellectual property portfolio, with multiple patent filings related to RNA splicing and gene expression technologies.
Tacit Therapeutics has positioned itself within a rapidly growing segment of biotechnology focused on RNA therapeutics, an area that has gained significant momentum following advances in mRNA-based medicines and gene modulation techniques. Investors in the space are increasingly targeting companies that can bridge the gap between foundational biological discoveries and scalable therapeutic platforms.
The company’s leadership team, led by CEO David Nelles, includes scientists and engineers with backgrounds in RNA biology, synthetic biology, and gene therapy development. Tacit emphasizes a data-driven research approach and aims to build a broad pipeline of therapies targeting multiple inherited conditions through its single platform technology.
As the gene therapy field becomes more competitive, Tacit Therapeutics is betting that RNA-level intervention will offer a safer and more flexible alternative to DNA editing approaches. The recent financing round provides the company with critical resources to continue advancing its scientific roadmap and strengthening its position in the emerging RNA therapeutics landscape.
